Numerous studies have demonstrated that EphB2 preferentially acts as a tumor suppressor in various cancers, including colorectal (CRC) (13), gastric (15) and prostate (14) cancer, which is unlike other RTKs that are generally regarded as oncogenes. The gene discussed is EPHB2; the disease is colorectal carcinoma.